March 2026 in “SHILAP Revista de lepidopterología” Rituximab may cause skin issues, but baricitinib can help improve them.
April 2023 in “Journal of Investigative Dermatology” Targeting mTOR in myeloid cells may help reduce psoriasis symptoms.
33 citations
,
May 2001 in “Annals of pharmacotherapy/The annals of pharmacotherapy” Topical tacrolimus is safe and effective for skin conditions, but oral tacrolimus has serious side effects.
101 citations
,
July 1998 in “Journal of Investigative Dermatology” UVB exposure in human skin causes macrophages to produce more IL-10 and less IL-12, leading to immunosuppression.
68 citations
,
September 2003 in “British Journal of Dermatology” Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.
January 2025 in “Clinical Case Reports” Timely and aggressive treatment is crucial for improving outcomes in severe complications of adult-onset Still's disease.
5 citations
,
April 2019 in “Journal of Investigative Dermatology” Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
July 2025 in “Dermatology Reports” Mesenchymal stem cell therapy shows promise for treating certain inflammatory skin diseases, but more research is needed.
15 citations
,
June 2015 in “F1000Research” Psoriasis may be chronic because it lacks certain immune system controls that prevent overreaction.
1 citations
,
September 2022 Distinguishing drug-induced lupus from systemic lupus is challenging and requires careful monitoring.
17 citations
,
May 2022 in “Frontiers in Immunology” Reprogramming macrophages to resolve inflammation can help reduce severe COVID-19 complications.
April 2023 in “Journal of Investigative Dermatology” Dimethyl fumarate speeds up wound healing in IL-36Ra deficient mice by reducing NET formation and oxidative stress.
1 citations
,
November 2020 in “International Journal of Dermatology” Methotrexate caused a rare skin rash in a rheumatoid arthritis patient, which resolved after stopping the drug.
6 citations
,
October 2024 in “Journal of Family Medicine and Primary Care” Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Researchers found that certain miRNAs, which affect immune system regulation, are differently expressed in mice with a hair loss condition compared to healthy mice.
60 citations
,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
MTX and GC combinations are the most effective for early rheumatoid arthritis.
1 citations
,
May 2023 in “Prospects in Pharmaceutical Sciences” New cytokine-targeted therapies show promise for treating alopecia areata.
39 citations
,
June 2023 in “Advanced Materials” Microneedles offer a promising, painless, and efficient way to deliver vaccines and therapies directly to the skin.
June 2024 in “Archives of Medical Science” Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.
September 2019 in “Philippine Journal of Internal Medicine” Early immunosuppressive therapy leads to favorable outcomes in Filipino lupus patients with myocarditis.
April 2023 in “Journal of Investigative Dermatology” The research developed methods to test drugs that could protect and restore hair follicle protection in a hair loss condition.
October 2025 in “Transactions on Materials Biotechnology and Life Sciences” Immunotherapies for non-small cell lung cancer show promise in improving treatment and reducing side effects.
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Mogamulizumab can cause hair loss, often linked to a better treatment response.
January 2024 in “Wiadomości Lekarskie” Multiomics is revolutionizing biology by enabling breakthroughs in research and disease diagnosis.
11 citations
,
September 2014 in “International Journal of Molecular Sciences” Mycophenolate helps reverse hair loss effects caused by IFN-γ by activating a key hair growth pathway.
May 2024 in “News Digital Object Group”
June 2020 in “Annals of the Rheumatic Diseases” Patients need better information about the risks of long-term steroid use.
72 citations
,
November 2015 in “Multiple Sclerosis and Related Disorders” Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
August 2023 in “Dermatology and Therapy” Imiquimod can cause rare skin side effects, some irreversible, and long-term follow-up is important for users.